The United Laboratories International Holdings Limited (03933.HK) Latest Company News

Aug 31, 2026, 19:00 UTC
United Laboratories International Holdings Limited reported interim results for the six months ended June 2026, with revenue of RMB 6.166 billion, down 18% year-on-year, and net profit of RMB 348 million, down 81.6% year-on-year.
Source:
- aastocks.com
Aug 28, 2026, 00:18 UTC
China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.
Source:
- finance.sina.cn
Aug 20, 2026, 01:23 UTC
United Laboratories issued a profit warning, expecting net profit of about RMB 340 million for the six months ended June 2026, down about 82% from RMB 1.893 billion a year earlier.
Source:
- aastocks.com
Aug 11, 2026, 14:30 UTC
Graviton BioScience received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for a capsule formulation of GV101 to treat Friedreich's ataxia on August 7, 2026.
Source:
- prnewswire.com
Aug 11, 2026, 14:07 UTC
United Laboratories announced that the U.S. FDA approved its IND application for UBT48128 tablets for overweight/obesity and type 2 diabetes indications.
Source:
- aastocks.com
Jul 16, 2026, 04:06 UTC
United Laboratories International Holdings Ltd (Federation Pharmaceuticals) received a milestone payment of US$13.5 million from Novo Nordisk under an exclusive license agreement for UBT251 injection for overweight or obesity indication global Phase II clinical trial.
Source:
Jul 15, 2026, 02:39 UTC
United Laboratories' wholly-owned subsidiary Zhuhai United Laboratories Zhongshan Branch received regulatory approval to market a new specification of sodium hyaluronate eye drops in China.
Source:
- aastocks.com

03933.HK

United Laboratories International Holdings Limited reported interim results for the six months ended June 2026, with revenue of RMB 6.166 billion, down 18% year-on-year, and net profit of RMB 348 million, down 81.6% year-on-year.

China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.

United Laboratories issued a profit warning, expecting net profit of about RMB 340 million for the six months ended June 2026, down about 82% from RMB 1.893 billion a year earlier.

Graviton BioScience received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for a capsule formulation of GV101 to treat Friedreich's ataxia on August 7, 2026.

United Laboratories announced that the U.S. FDA approved its IND application for UBT48128 tablets for overweight/obesity and type 2 diabetes indications.

United Laboratories International Holdings Ltd (Federation Pharmaceuticals) received a milestone payment of US$13.5 million from Novo Nordisk under an exclusive license agreement for UBT251 injection for overweight or obesity indication global Phase II clinical trial.

United Laboratories' wholly-owned subsidiary Zhuhai United Laboratories Zhongshan Branch received regulatory approval to market a new specification of sodium hyaluronate eye drops in China.